Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR
Objective: The pathologic complete response (pCR) in the breast and axillary lymph node after neoadjuvant chemotherapy (NAC) would improve outcomes and it is used as a surrogate marker for survival. Our objective was to evaluate the breast and nodal pCR in breast cancer patients with estrogen recept...
Main Authors: | Ramesh Omranipour, Roghiyeh Jalili, Adel Yazdankhahkenary, Abdolali Assarian, Mehrzad Mirzania, Bita Eslami |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2020-07-01
|
Series: | European Journal of Breast Health |
Subjects: | |
Online Access: |
http://www.eurjbreasthealth.com/archives/archive-detail/article-preview/evaluation-of-pathologic-complete-response-pcr-to-/41916
|
Similar Items
-
Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
by: Nandini Dey, et al.
Published: (2021-01-01) -
Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses
by: Jin Y, et al.
Published: (2023-05-01) -
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01) -
Prediction of pCR based on clinical-radiomic model in patients with locally advanced ESCC treated with neoadjuvant immunotherapy plus chemoradiotherapy
by: Xiaohan Wang, et al.
Published: (2024-03-01) -
Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)